Literature DB >> 21151099

VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma.

Adriana von Teichman1, Eva Compérat, Silvia Behnke, Martina Storz, Holger Moch, Peter Schraml.   

Abstract

Multilocular cystic renal cell carcinoma is a rare renal cell carcinoma with an excellent prognosis. To clarify the relationship with typical clear cell renal cell carcinoma, we evaluated 15 cases of multilocular cystic renal cell carcinomas diagnosed according to the 2004 WHO classification. Von Hippel Lindau (VHL) gene mutations were determined by whole genome amplification and direct sequencing. Carbonic anhydrase 9 (CAIX), a hypoxia-inducible factor (HIF) target, paired box gene 2 (PAX2), cyclin-dependent kinase inhibitor p27 and glycogen synthase kinase 3-β (GSK3β) were immunohistochemically evaluated as members of the VHL protein (pVHL)- and phosphatase and tensin homolog (PTEN)-controlled pathways. VHL mutations were identified in 3 of 12 (25%) tumors. Inactivated GSK3β, decreased PTEN expression and PAX2 positivity were observed in the vast majority of the multilocular cystic renal cell carcinomas. Strong nuclear staining of p27 was seen in 14 of 15 cases. Compared with multilocular cystic renal cell carcinomas, expression frequencies of PAX2, p-GSK3β, PTEN and CAIX were similar in a set of low-grade, early-stage clear cell renal cell carcinomas, whereas only 30% had strong p27 positivity. These results are consistent with the hypothesis that multilocular cystic renal cell carcinomas are related at the molecular level with clear cell renal cell carcinomas. Maintenance of a strong subcellular p27 expression in all multilocular cystic renal cell carcinomas analyzed may in part explain the excellent prognosis of these tumor patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21151099     DOI: 10.1038/modpathol.2010.222

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

3.  Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?

Authors:  Adriana von Teichman; Martina Storz; Susanne Dettwiler; Holger Moch; Peter Schraml
Journal:  Virchows Arch       Date:  2012-09-25       Impact factor: 4.064

4.  Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential.

Authors:  Maria Rosaria Raspollini; Francesca Castiglione; Guido Martignoni; Liang Cheng; Rodolfo Montironi; Antonio Lopez-Beltran
Journal:  Virchows Arch       Date:  2015-10-05       Impact factor: 4.064

5.  [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

6.  Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum.

Authors:  Maria Tretiakova; Vikas Mehta; Masha Kocherginsky; Agata Minor; Steven S Shen; Sahussapont Joseph Sirintrapun; Jorge L Yao; Isabel Alvarado-Cabrero; Tatjana Antic; Scott E Eggener; Maria M Picken; Gladell P Paner
Journal:  Virchows Arch       Date:  2018-05-17       Impact factor: 4.064

7.  Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Authors:  Allison B Weisbrod; Lisa Zhang; Meenu Jain; Stephanie Barak; Martha M Quezado; Electron Kebebew
Journal:  Horm Cancer       Date:  2013-01-30       Impact factor: 3.869

8.  Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation.

Authors:  Holger Lehmann; Daniele Vicari; Peter J Wild; Ian J Frew
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

9.  The Role of PTEN in Tumor Angiogenesis.

Authors:  Stéphane Rodriguez; Uyen Huynh-Do
Journal:  J Oncol       Date:  2011-09-05       Impact factor: 4.375

10.  Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice.

Authors:  Joachim Albers; Michal Rajski; Désirée Schönenberger; Sabine Harlander; Peter Schraml; Adriana von Teichman; Strahil Georgiev; Peter J Wild; Holger Moch; Wilhelm Krek; Ian J Frew
Journal:  EMBO Mol Med       Date:  2013-04-22       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.